Free
Pain Medicine  |   April 2003
Optimal Adrenergic Support in Septic Shock Due to Peritonitis
Author Affiliations & Notes
  • Qinghua Sun, M.D., Ph.D.
    *
  • Zizhi Tu, M.D.
    *
  • Suzana Lobo, M.D.
    *
  • George Dimopoulos, M.D.
    *
  • Nathalie Nagy, M.D.
  • Peter Rogiers, M.D.
  • Daniel De Backer, M.D., Ph.D.
  • Jean-Louis Vincent, M.D., Ph.D.
    §
  • *Research Fellow, †Staff Physician, §Head, Department of Intensive Care, Erasme Hospital, Free University of Brussels. ‡Staff Physician, Department of Intensive Care, Middelheim General Hospital.
  • Received from the Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium, and the Department of Intensive Care, Middelheim General Hospital, Antwerp, Belgium.
Article Information
Pain Medicine
Pain Medicine   |   April 2003
Optimal Adrenergic Support in Septic Shock Due to Peritonitis
Anesthesiology 4 2003, Vol.98, 888-896. doi:
Anesthesiology 4 2003, Vol.98, 888-896. doi:
SEPTIC shock is characterized by peripheral vasodilatation, myocardial depression, and ineffective cellular oxygen utilization leading to multiple organ failure. The clinical presentation is characterized by systemic hypotension, a normal or high cardiac output, decreased systemic vascular resistance (SVR), and signs of altered organ perfusion. In addition to plasma volume expansion, hemodynamic stabilization often requires the administration of vasoactive and/or inotropic agents to maintain mean arterial pressure (MAP) and cardiac output.
Dopamine is commonly used first in septic shock for its combined α, β, and dopaminergic properties, resulting in combined increases in MAP, cardiac output, and selective increases in renal and splanchnic blood flows. 1,2 Some clinicians, however, prefer the early administration of norepinephrine, a potent α-adrenergic agonist with less pronounced β-adrenergic agonist effects, which can more effectively increase vascular tone. Norepinephrine administration in septic shock usually increases MAP by increasing SVR while maintaining cardiac index. 1–3 Norepinephrine administration in septic patients is sometimes associated with restoration of urine output and improvement in renal function 4 and metabolism, including an effective reduction of lactic acidosis. 5 Although norepinephrine sometimes has been reported to increase gastric intramucosal pH (pHi), its effects on splanchnic blood flow can be variable. 6–8 
Dobutamine is also used frequently in septic shock patients as an inotropic agent to increase cardiac output, stroke index, and oxygen delivery (Do2). Dobutamine does not significantly influence the distribution of blood flow 9 but can prevent intestinal arteriolar constriction and restore villus blood flow. 10 In clinical trials, dobutamine in doses ranging from 5–20 μg · kg−1· min−1was found to increase Do2and oxygen consumption (V̇o2), 11–15 to reverse gastric intramucosal acidosis, 16 and to ameliorate renal function. 17 However, the lack of benefit, 18 and even possible harm, 19 of dobutamine administration to increase Do2to supranormal values in critically ill patients has raised questions regarding its use in the treatment of septic shock.
In the absence of randomized clinical trials, optimal adrenergic support in septic shock is still controversial. In the current study, we sought to define the optimal adrenergic regimen in a clinically relevant experimental model of septic shock. We hypothesized that the addition of dopamine or dobutamine to norepinephrine could result in better tissue oxygenation associated with prolonged survival. In controlled, randomized experiments in a septic shock sheep model induced by peritonitis, we studied the effects of norepinephrine alone, dopamine with norepinephrine, and dobutamine with norepinephrine on global and regional hemodynamics, arterial blood lactate concentrations, histologic changes, and survival time.
Materials and Methods
Experimental Preparation
This study was approved by our Institutional Review Board for animal care (Brussels, Belgium). Care and handling of the animals were in accord with National Institutes of Health guidelines. Twenty-eight mature, female sheep (weight, 30.5 ± 3.6 kg) were included in the study. After tracheal intubation under intramuscular injection of 2 ml xylazine (Bayer, Leverkusen, Germany) and 3 ml ketamine (Ketalar®; Warner-Lambert Manufacturing Ltd., Dublin, Ireland), each sheep was anesthetized with infusion of a mixture of midazolam (Dormicum®; Hoffmann-La Roche, Basel, Switzerland) and fentanyl (Janssen Pharmaceutica, Beerse, Belgium) using an infusion pump (Perfusor® secura; Braun, Melsungen AG, Germany) and mechanically ventilated with an inspired oxygen fraction (Fio2) of 0.5 (Servo ventilator 900B; Siemens-Elema, Solna, Sweden). Muscle paralysis was obtained by the administration of pancuronium bromide, administered at an initial dose of 0.15 mg/kg and subsequent infusion of 0.075 mg · kg−1· h−1. Respiratory rate was 14 breaths/min, and tidal volume was adapted to keep end-tidal partial pressure of carbon dioxide (Pco2; 47210A Capnometer; Hewlett-Packard, Waltham, MA) between 28 and 38 mmHg. The left forepaw vein was catheterized for the intravenous administration of anesthetic agent and pancuronium bromide. The right forepaw vein was catheterized for intravenous infusion of lactated Ringer's solution. The right femoral artery was catheterized for monitoring of arterial blood pressure and withdrawal of arterial blood samples. Through the right jugular vein, a balloon-tip pulmonary artery catheter (93A-439H-7.5F; Baxter Edwards Critical-Care, Irvine, CA) was placed under guidance of pressure waves (Sirecust™ monitor 404; Siemens, Davis, CA).
Through a midline laparotomy, the cecal and ileocecal junction was identified. After a 1-cm perforation in the cecal tip, fecal material (approximately 30 ml) was spilled into the peritoneal cavity toward the right lower quadrant. Ultrasonic flow probes (Transonic® Flowprobe; Transonic Systems Inc., Ithaca, NY) were placed around the left femoral artery and the superior mesenteric artery for simultaneous determinations of regional blood flow. A tonometric catheter (TRIP, NGS catheter; Tonometrics, Helsinki, Finland) was inserted into the ileum to measure ileal intramucosal carbon dioxide tension 20,21 (in a pilot study, gastric tonometry was found to be unreliable in these ruminant animals), and the abdomen was closed with a running suture of 0 Dexon® (Davis & Geck, Wayne, NJ). During the whole experiment, feces were not removed, and the peritoneal cavity was not washed. A Foley catheter was introduced via  the urethra to collect urine.
In each group, fluid maintenance was approximately 1,000 ml lactated Ringer's solution during the course of surgery, titrated to keep the pulmonary artery occlusion pressure (PAOP) constant as at the first measurement. Body temperature was kept below 41°C by ice package. In pilot experiments, the polymicrobial peritonitis and bacteremia were confirmed by blood cultures.Organisms most frequently grown included Klebsiella oxytoca  , Enterobacter cloaceae  , Enterococcus faecalis  , Citrobacter freundii  and various strains of Escherichia coli  .
Experimental Protocol
The sheep were randomly allocated to one of the four experimental groups of seven sheep each.
Group 1: Control.
No adrenergic agent was administered.
Group 2: Norepinephrine.
When MAP decreased to a value less than 75 mmHg, a norepinephrine infusion (Levophed®; Sanofi-Pharma, New York, NY; 8 mg/4 ml) was started at an initial rate of 0.5 μg · kg−1· min−1and increased by 0.5-μg · kg−1· min−1increments up to a maximum of 5 μg · kg−1· min−1to maintain MAP between 75 and 85 mmHg.
Group 3: Dopamine-Norepinephrine.
When MAP decreased to a value less than 75 mmHg, a dopamine (Dynatra 200; Sintesa, Brussels, Belgium; 200 mg/5 ml) infusion was started and titrated to maintain MAP between 75 and 85 mmHg. The initial rate was 5 μg · kg−1· min−1and increased by 2.5-μg · kg−1· min−1increments up to a maximum rate of 20 μg · kg−1· min−1. If MAP remained lower than 75 mmHg with a dose of 20 μg · kg−1· min−1, a norepinephrine infusion was added at an initial concentration of 0.5 μg · kg−1· min−1and increased up to 5 μg · kg−1· min−1, as in group 2.
Group 4: Dobutamine-Norepinephrine.
Treatment was identical to that of group 2 except that dobutamine (Dobutrex®; Eli Lilly, Indianapolis, IN; 250 mg/ 20 ml) was added at the same time as norepinephrine and titrated to obtain a 15% increase in cardiac output. The infusion rate was initially 5 μg · kg−1· min−1and increased by 2.5-μg · kg−1· min−1increments up to a maximum of 20 μg · kg−1· min−1.
In each sheep, the administration of lactated Ringer's solution was titrated to keep PAOP as close as possible to the baseline value, and the doses of adrenergic agents were titrated at 5-min intervals. Potassium chloride was added to lactated Ringer's solution as needed to keep plasma potassium concentration between 3.5 and 5.0 mm.
One hour was allowed before the first measurements (as baseline values) were taken. Measurements were repeated every hour throughout the experiment and included MAP, pulmonary arterial pressure, PAOP, right atrial pressure, cardiac output, femoral and superior mesenteric arterial blood flows, expired oxygen fraction, end-tidal Pco2, minute volume, blood gases, arterial hemoglobin concentration, blood arterial lactate concentration, plasma electrolytes concentration, infusion volume, and urinary output. The survival time was also recorded.
Pressures were monitored continuously, using a pressure monitoring kit (Baxter, Uden, Holland) with amplifiers (Servomed; Hellige, Freiburg, Germany) and a pen recorder (2600S; Gould, Instruments Division, Cleveland, OH). All pressures were determined at end-expiration. Cardiac output was measured in triplicate by the thermodilution technique (Swan-Ganz Catheter; Baxter, Irvine, CA), using 10-ml iced saline solution (0°C) at end-expiration. Stroke volume (SV), SVR, pulmonary vascular resistance (PVR), and left ventricular stroke work (LVSW) were calculated by standard formula. Superior mesenteric and femoral artery blood flows were simultaneously measured by ultrasound volume flowmeter (T208; Transonic Systems Inc.; calibrated by the manufacturer).
Exhaled gases were passed directly through a mixing chamber for sampling of expired oxygen fractions (P.K. Morgan Ltd., Chatham, Kent, United Kingdom). Expired minute volume was measured with a spirometer (Haloscale Respirometer; Wright, Edronton, London, United Kingdom) over a 2-min period. Arterial and mixed venous blood samples were simultaneously withdrawn for immediate determination of blood gases (ABL625; Radiometer, Copenhagen, Denmark), arterial and mixed venous oxygen saturations, and total hemoglobin (OSM 3 Hemoximeter; Radiometer). Blood lactate and electrolyte (K+, Na+, Ca2+, Cl) concentrations were determined by an automated analyzer (ABL625; Radiometer). Ptco2was measured by saline tonometry using the standard technique. The tonometer balloon was filled with 2.5 ml saline and allowed to equilibrate for approximately 60 min. Saline was anaerobically aspirated, the first milliliter was discarded, and the remaining 1.5 ml was analyzed immediately using the blood gas analyzer. The Pco2gap was calculated as the difference between Ptco2and arterial Pco2. Do2, V̇o2, and oxygen extraction ratio were derived from standard equations.
Postmortem Examination
When the sheep died, tissue samples were surgically excised from the lung, the liver, the gut, and the kidney and immediately immersed in 4% formalin (pH = 7). The samples were sectioned and stained with hematoxylin and eosin for light microscopy. All biopsies were coded to enable processing and evaluation. A pathologist unfamiliar with the conditions of the study examined all fields of the slides in a blinded fashion, and 10 micrographs from each specimen were taken from consecutive squares. Anatomic abnormalities were recorded semiquantitatively as focal cell injury, edema, and acute inflammation. The degree of each abnormality was graded numerically from 0 (normal) to 3 (most severe) in the intestine specimens and from 0 (normal) to 2 (most severe) in the other specimens. 22 
Statistical Analysis
Data were analyzed using a two-way analysis of variance for repeated measurements followed by a Newman-Keuls procedure. Missing values were estimated using the method proposed by Yates that minimizes the error sum of squares. 23 The error degree of freedom is reduced by the number of missing data. By doing this, (1) the estimates of group and time effects are exactly the same as those obtained by the correct least square procedure, and (2) the error sum of squares is exactly the same as given by the correct procedure. The correct least square approach used the type III or type IV sum of squares in which the characteristics equations are solved by the general inverse technique. A Kruskal-Wallis test was used to evaluate the differences in the degrees of anatomic abnormalities. To evaluate survival time, Kaplan-Meier survival curves were constructed and analyzed by the Mantel-Cox log-rank test. P  < 0.05 was considered statistically significant. All values are expressed as mean ± SD, except when mentioned otherwise.
Results
No significant differences were observed between the four groups in baseline hemodynamic and metabolic parameters (table 1). All animals developed severe hyperthermia requiring ice cooling. The control group was characterized by arterial hypotension, tachycardia, increased cardiac output, and low SVR. The mean amount of fluid administered was 10–15 ml · kg−1· h−1; there were no statistical differences among groups in the amount of fluid administered. Blood cultures were performed consecutively in the first three sheep and showed positive and consistent results in all three animals. The start time of adrenergic treatment after the end of the surgical procedure was 9.7 ± 2.1 h in the norepinephrine group, 10.0 ± 2.3 h in the dopamine-norepinephrine group, and 9.9 ± 2.4 h in the dobutamine-norepinephrine group, respectively (differences not significant). In all sheep in the dopamine-norepinephrine group, norepinephrine had to be added to dopamine within 2 h of dopamine administration to maintain MAP.
Table 1. Hemodynamic and Metabolic Parameters
Image not available
Table 1. Hemodynamic and Metabolic Parameters
×
Mean arterial pressure was well maintained for at least 15 h in all treatment groups (fig. 1). Cardiac output increased in all groups, but this increase was maintained only in the dobutamine-norepinephrine group (fig. 1), partly because of an increase in heart rate. LVSW transiently increased in all treatment groups, and this increase was prolonged in the dobutamine-norepinephrine group. SVR increased in the dopamine-norepinephrine and norepinephrine groups but decreased in the dobutamine-norepinephrine group (table 1). Superior mesenteric blood flow increased in all groups, but this increase was maintained only in the dobutamine-norepinephrine group (fig. 2). Do2increased significantly in all treatment groups, especially in the dobutamine-norepinephrine group. Toward the end of the experiment, Do2and V̇o2were greater in the dobutamine-norepinephrine group than in the dopamine-norepinephrine or norepinephrine alone group (table 1).
Fig. 1. Changes in mean arterial blood pressure (top  ) and cardiac output (bottom  ) in the four groups. Base represents the first measurement after 1 h of stabilization following laparotomy. Adrenergic agents were required after a mean of approximately 10 h. *P  < 0.05, control (CL) versus  dobutamine (DB)-norepinephrine (NE); #P  < 0.05, CL versus  norepinephrine; =P  < 0.05, dopamine (DP)-norepinephrine versus  dobutamine-norepinephrine.
Fig. 1. Changes in mean arterial blood pressure (top 
	) and cardiac output (bottom 
	) in the four groups. Base represents the first measurement after 1 h of stabilization following laparotomy. Adrenergic agents were required after a mean of approximately 10 h. *P 
	< 0.05, control (CL) versus 
	dobutamine (DB)-norepinephrine (NE); #P 
	< 0.05, CL versus 
	norepinephrine; =P 
	< 0.05, dopamine (DP)-norepinephrine versus 
	dobutamine-norepinephrine.
Fig. 1. Changes in mean arterial blood pressure (top  ) and cardiac output (bottom  ) in the four groups. Base represents the first measurement after 1 h of stabilization following laparotomy. Adrenergic agents were required after a mean of approximately 10 h. *P  < 0.05, control (CL) versus  dobutamine (DB)-norepinephrine (NE); #P  < 0.05, CL versus  norepinephrine; =P  < 0.05, dopamine (DP)-norepinephrine versus  dobutamine-norepinephrine.
×
Fig. 2. Changes in superior mesenteric artery (top  ) and femoral artery (bottom  ) blood flow in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
Fig. 2. Changes in superior mesenteric artery (top 
	) and femoral artery (bottom 
	) blood flow in the four groups. See figure 1for other details. =P 
	< 0.05, dopamine (DP)-norepinephrine (NE) versus 
	dobutamine (DB)-norepinephrine.
Fig. 2. Changes in superior mesenteric artery (top  ) and femoral artery (bottom  ) blood flow in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
×
Blood lactate concentration and Pco2gap increased less in the dobutamine-norepinephrine group than in the control group (fig. 3). Cumulative urine output was significantly higher in the dobutamine-norepinephrine group than in the other groups (fig. 4).
Fig. 3. Changes of lactate concentration in arterial blood (top  ) and Pco2gap (bottom  ) in the four groups. See figure 1for other details. *P  < 0.05, CL versus  dobutamine (DB)-norepinephrine (NE); +P  < 0.05, norepinephrine versus  dobutamine- norepinephrine.
Fig. 3. Changes of lactate concentration in arterial blood (top 
	) and Pco2gap (bottom 
	) in the four groups. See figure 1for other details. *P 
	< 0.05, CL versus 
	dobutamine (DB)-norepinephrine (NE); +P 
	< 0.05, norepinephrine versus 
	dobutamine- norepinephrine.
Fig. 3. Changes of lactate concentration in arterial blood (top  ) and Pco2gap (bottom  ) in the four groups. See figure 1for other details. *P  < 0.05, CL versus  dobutamine (DB)-norepinephrine (NE); +P  < 0.05, norepinephrine versus  dobutamine- norepinephrine.
×
Fig. 4. Cumulative urine output in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
Fig. 4. Cumulative urine output in the four groups. See figure 1for other details. =P 
	< 0.05, dopamine (DP)-norepinephrine (NE) versus 
	dobutamine (DB)-norepinephrine.
Fig. 4. Cumulative urine output in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
×
Three of seven sheep survived longer than 24 h in the dobutamine-norepinephrine group, two of seven survived longer than 24 h in the dopamine-norepinephrine group, and none survived longer than 24 h in the norepinephrine or control groups. The mean survival time was 17 ± 2 h in the control group, 20 ± 1 h in the norepinephrine group, 24 ± 6 h in the dopamine-norepinephrine group, and 24 ± 5 h in the dobutamine-norepinephrine group. The survival time was significantly longer in all treatment groups than in the control group (P  < 0.05;fig. 5). The survival time was also significantly longer in the dobutamine-norepinephrine and dopamine-norepinephrine groups than in the norepinephrine alone group (P  < 0.05).
Fig. 5. Kaplan-Meier survival curves for the four groups: control (▪), norepinephrine (▾), dopamine-norepinephrine (▴), and dobutamine-norepinephrine (⧫). P  < 0.05, control (CL) versus  dopamine-norepinephrine, norepinephrine, or dobutamine-norepinephrine, or norepinephrine versus  dopamine-dobuta-mine-norepinephrine.
Fig. 5. Kaplan-Meier survival curves for the four groups: control (▪), norepinephrine (▾), dopamine-norepinephrine (▴), and dobutamine-norepinephrine (⧫). P 
	< 0.05, control (CL) versus 
	dopamine-norepinephrine, norepinephrine, or dobutamine-norepinephrine, or norepinephrine versus 
	dopamine-dobuta-mine-norepinephrine.
Fig. 5. Kaplan-Meier survival curves for the four groups: control (▪), norepinephrine (▾), dopamine-norepinephrine (▴), and dobutamine-norepinephrine (⧫). P  < 0.05, control (CL) versus  dopamine-norepinephrine, norepinephrine, or dobutamine-norepinephrine, or norepinephrine versus  dopamine-dobuta-mine-norepinephrine.
×
Results of anatomic examination of the organs are shown in figure 6. Lung biopsies revealed variable degrees of inflammatory change from interstitial to alveolar edema and congestive atelectasis to severe injuries, including diffuse alveolar damage with exudation in the interstitium and alveolar spaces, and hemorrhagic alveolitis. Inflammation and edema formation were less severe in the dopamine-norepinephrine and dobutamine-norepinephrine groups (P  < 0.02 for all groups). Liver alterations were characterized by congestion, sinusoidal pericentrolobular dilatation, and necrosis. These alterations were least severe in the dobutamine-norepinephrine group (P  < 0.05 for all groups). Small intestine congestion and edema were also least severe in the dobutamine-norepinephrine group than in the other groups (P  < 0.01 for all groups). Kidney examination showed only congestion. Figure 7shows light micrographs of pulmonary, hepatic, and renal biopsies from one sheep in the control group.
Fig. 6. Histologic alterations in the small intestine and lung. Open bars represent the number of animals in which an alteration was observed, and solid bars represent the sum of the severity scores for each type of alteration in the entire group. CL = control group; NE = norepinephrine; DP+NE = dopamine-norepinephrine; DB+ NE = dobutamine-norepinephrine; C = congestion; I = interstitial inflammation; E = edema; H = hemorrhagic alveolitis. *P  < 0.05 versus  CL.
Fig. 6. Histologic alterations in the small intestine and lung. Open bars represent the number of animals in which an alteration was observed, and solid bars represent the sum of the severity scores for each type of alteration in the entire group. CL = control group; NE = norepinephrine; DP+NE = dopamine-norepinephrine; DB+ NE = dobutamine-norepinephrine; C = congestion; I = interstitial inflammation; E = edema; H = hemorrhagic alveolitis. *P 
	< 0.05 versus 
	CL.
Fig. 6. Histologic alterations in the small intestine and lung. Open bars represent the number of animals in which an alteration was observed, and solid bars represent the sum of the severity scores for each type of alteration in the entire group. CL = control group; NE = norepinephrine; DP+NE = dopamine-norepinephrine; DB+ NE = dobutamine-norepinephrine; C = congestion; I = interstitial inflammation; E = edema; H = hemorrhagic alveolitis. *P  < 0.05 versus  CL.
×
Fig. 7. Representative light micrographs of pulmonary, hepatic, and renal biopsies in one sheep from the control group (sheep No. 5801, hematoxylin and eosin, ×100). Kidney (top left  ); lung (bottom left  ); liver (bottom right  ).
Fig. 7. Representative light micrographs of pulmonary, hepatic, and renal biopsies in one sheep from the control group (sheep No. 5801, hematoxylin and eosin, ×100). Kidney (top left 
	); lung (bottom left 
	); liver (bottom right 
	).
Fig. 7. Representative light micrographs of pulmonary, hepatic, and renal biopsies in one sheep from the control group (sheep No. 5801, hematoxylin and eosin, ×100). Kidney (top left  ); lung (bottom left  ); liver (bottom right  ).
×
Discussion
The current peritonitis model produced by the spillage of feces followed by generous fluid administration reproduces many of the clinical features of human septic shock, including hyperthermia, arterial hypotension, tachycardia, increased cardiac output, low SVR, and hyperlactatemia. The model is characterized by large fluid requirements (10–15 ml · kg−1· h−1) to achieve this hyperkinetic state. In the absence of antibiotic administration and with no other support than intravenous fluid loading, the model is lethal after 15–20 h. Although we acknowledge that the use of anesthesia may have influenced our results, ketamine is the anesthetic agent with the fewest cardiovascular effects in septic shock. 24 Recent experimental studies have suggested a gender advantage for proestrus female mice over males in survival from sepsis, 25 and ovariectomized mice had a higher death rate than proestrus mice after cecal ligation and puncture. 26 These potential difference were limited in the current study by using only female sheep, and although the estrus state of individual sheep was not measured, the randomization of the sheep into the four study groups should have limited any potential influence of varying concentrations of female hormones on the response to sepsis.
Dopamine is often recommended as the first-line agent to correct fluid resistant hypotension, 1,2 but its use has been challenged recently on the basis that the dopaminergic effects have not been shown to be beneficial. 27 It has also been argued that dopamine is not very effective, so that in many patients, an adequate tissue perfusion pressure cannot be obtained with the use of dopamine alone, even at doses as high as 80 μg · kg−1· min−1. 28,29 In a porcine endotoxic shock model, Sautner et al.  30 found that the administration of norepinephrine did not improve endotoxin-induced damage of the ileum and colon mucosa. However, low-dose (3 μg · kg−1· min−1) dopamine administration delayed and attenuated the decrease in intestinal villus blood during normotensive endotoxemia in the rat. 31 In the current study, dopamine alone was insufficient to maintain cardiac output or MAP, and norepinephrine had to be added within 2 h after the onset of dopamine infusion. By its stronger α-adrenergic effect on vascular tone, norepinephrine effectively corrected hypotension. Nevertheless, cardiac output and LVSW increased with dopamine, and MAP was better maintained by the combination of dopamine with norepinephrine than by norepinephrine alone.
Dobutamine is the catecholamine of choice to increase myocardial contractility, cardiac output, and Do2. 13,32–35 The addition of dobutamine to vasopressor regimens can markedly increase Do2and Vo2in septic patients. 36,37 Martin et al.  38 found that the addition of dobutamine to norepinephrine in septic shock patients significantly improved MAP, cardiac output, SV, and LVSW. In a rat model, dobutamine prevented intestinal arteriolar constriction and maintained villus blood flow at preendotoxemic values, 39 and in a porcine model of endotoxic shock, dobutamine also increased blood flow to the gastrointestinal mucosa. 40 The vasodilating effect of dobutamine on gastric mucosal microcirculation has also been noted in humans. 41 In our study, addition of dobutamine to norepinephrine increased cardiac output and resulted in higher MAP, SV, cardiac output, and LVSW when compared with the combination of dopamine with norepinephrine or norepinephrine alone during the final stages of the experiment.
Superior mesenteric blood flow was better maintained in the dobutamine-norepinephrine group than in the other groups, reflecting an improvement in splanchnic perfusion. Several studies have shown that dobutamine can decrease Pco2gap and increase pHi. 16,41 Although the use of the tonometer in ruminant animals may be problematic, the ileal Pco2gap increased less in the dobutamine-norepinephrine group than in the other groups. Blood lactate concentrations were significantly lower in the dobutamine-norepinephrine group than in the control group. Even though the increase in lactate concentrations in sepsis can result from many complex cellular mechanisms other than just tissue hypoxia, including catecholamine-stimulated aerobic glycolysis, 42 the earlier reduction in blood lactate concentrations suggests a more effective improvement in cellular metabolism and is associated with improved outcome. 43 
Our model also allowed us to study the effects of adrenergic support on survival. Lower mortality rates have been reported for patients who reached supranormal values of Do2with adrenergic support. 15,44 Recently, Rivers et al.  45 showed that aggressive resuscitation regimens targeting venous oxygen saturation increased survival rates in severe sepsis and septic shock. However, detrimental effects have also been observed when therapy is oriented to supranormal Do2and V̇o2levels in critically ill patients. 19 In the current study, the combination of norepinephrine with dobutamine or dopamine prolonged survival.
Globally, the dobutamine-norepinephrine group showed the least anatomic damage to the organs, suggesting the beneficial effects of a higher Do2to these organs. In a porcine model of fecal peritonitis, Tighe et al.  46,47 found that dobutamine had detrimental effects on the histology in the liver, with marked hepatocellular damages. Our current study does not support these findings, perhaps because our peritonitis model is less acute, fluid administration was more generous, and the dose of dobutamine was limited to a maximum of 20 μg · kg−1· min−1as currently recommended. 1 
In this hyperdynamic septic shock model, we conclude that, when volume replacement is adequate and perfusion pressure is well maintained by vasopressor therapy, dopamine alone is insufficient to maintain cardiac output or MAP. The combination of norepinephrine with either dopamine or dobutamine is more efficient than norepinephrine alone in reversing the hemodynamic abnormalities, alleviating the histologic injury in the major organs, and prolonging survival. In particular, the combination of norepinephrine with dobutamine can limit the increase in arterial lactate concentration and Pco2gap and attenuate anatomic damage to the lung, liver, and small intestine. These data caution against the use of norepinephrine alone in the treatment of hypotension in septic shock.
References
Task Force of the American College of Critical Care Medicine SCCM: Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27: 639–60Task Force of the American College of Critical Care Medicine SCCM:,
Vincent JL: Hemodynamic support in septic shock: Guidelines for the management of severe sepsis and septic shock. International Sepsis Forum. Intensive Care Med 2001; 27 Suppl 1: S80–92Vincent, JL
Karzai W, Reilly JM, Hoffman WD, Cunnion RE, Danner RL, Banks SM, Parrillo JE, Natanson C: Hemodynamic effects of dopamine, norepinephrine, and fluids in a dog model of sepsis. Am J Physiol 1995; 268: H692–702Karzai, W Reilly, JM Hoffman, WD Cunnion, RE Danner, RL Banks, SM Parrillo, JE Natanson, C
Desjars Ph, Pinaud M, Bugnon D, Tasseau F: Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989; 17: 426–9Desjars, Ph Pinaud, M Bugnon, D Tasseau, F
Martin C, Papazian L, Perrin G, Saux P, Gouin F: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103: 1826–31Martin, C Papazian, L Perrin, G Saux, P Gouin, F
Ruokonen E, Takala J, Kari A, Saxen H, Mertsola J, Hansen EJ: Regional blood flow and oxygen transport in septic shock. Crit Care Med 1993; 21: 1296–303Ruokonen, E Takala, J Kari, A Saxen, H Mertsola, J Hansen, EJ
Marik PE, Mohedin J: The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354–7Marik, PE Mohedin, J
Zhang H, Smail N, Cabral A, Rogiers P, Vincent JL: Effects of norepinephrine on regional blood flow and oxygen extraction capabilities during endotoxic shock. Am J Respir Crit Care Med 1997; 155: 1965–71Zhang, H Smail, N Cabral, A Rogiers, P Vincent, JL
Van Lambalgen AA, Van Kraats AA, Mulder MF, Van den Bos GC, Teerlink T, Thijs LG: Organ blood flow and distribution of cardiac output in dopexamine- or dobutamine-treated endotoxemic rats. J Crit Care 1993; 8: 117–27Van Lambalgen, AA Van Kraats, AA Mulder, MF Van den Bos, GC Teerlink, T Thijs, LG
Gnidec AG, Finley RR, Sibbald WJ: Effect of dobutamine on lung microvascular fluid flux in sheep with “sepsis syndrome.” Chest 1988; 93: 180–6Gnidec, AG Finley, RR Sibbald, WJ
Shoemaker WC, Appel PL, Kram HB: Hemodynamic and oxygen transport effects of dobutamine in critically ill general surgical patients. Crit Care Med 1986; 14: 1032–7Shoemaker, WC Appel, PL Kram, HB
Vincent JL, Roman A, De Backer D, Kahn RJ: Oxygen uptake/supply dependency: Effects of short-term dobutamine infusion. Am Rev Respir Dis 1990; 142: 2–8Vincent, JL Roman, A De Backer, D Kahn, RJ
Shoemaker WC, Appel PL, Kram HB: Oxygen transport measurements to evaluate tissue perfusion and titrate therapy: Dobutamine and dopamine effects. Crit Care Med 1991; 19: 672–88Shoemaker, WC Appel, PL Kram, HB
Tuchschmidt J, Fried J, Astiz M, Rackow E: Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102: 216–20Tuchschmidt, J Fried, J Astiz, M Rackow, E
Yu M, Levy MM, Smith P, Takiguchi SA, Miyasaki A, Myers SA: Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: A prospective, randomized, controlled study. Crit Care Med 1993; 21: 830–8Yu, M Levy, MM Smith, P Takiguchi, SA Miyasaki, A Myers, SA
Silverman H, Tuma P: Gastric tonometry in patients with sepsis: Effects of dobutamine infusions and packed red blood cell transfusions. Chest 1992; 102: 184–8Silverman, H Tuma, P
Duke GJ, Briedis JH, Weaver RA: Renal support in critically ill patients: Low-dose dopamine or low-dose dobutamine. Crit Care Med 1994; 22: 1919–25Duke, GJ Briedis, JH Weaver, RA
Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333: 1025–32Gattinoni, L Brazzi, L Pelosi, P Latini, R Tognoni, G Pesenti, A Fumagalli, R
Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D: Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717–22Hayes, MA Timmins, AC Yau, EH Palazzo, M Hinds, CJ Watson, D
Revelly JP, Ayuse T, Brienza N, Fessler HE, Robotham JL: Endotoxic shock alters distribution of blood flow within the intestinal wall. Crit Care Med 1996; 24: 1345–51Revelly, JP Ayuse, T Brienza, N Fessler, HE Robotham, JL
Knichwitz G, Brussel T, Reinhold P, Schaumann F, Richter KD, Van Aken H: Early onset of regional intestinal ischemia can be detected with carbon dioxide tension measurement inside the peritoneal cavity. Anesth Analg 2000; 91: 1182–7Knichwitz, G Brussel, T Reinhold, P Schaumann, F Richter, KD Van Aken, H
Elgjo GI, Traber DL, Hawkins HK, Kramer GC: Burn resuscitation with two doses of 4 mL/kg hypertonic saline dextran provides sustained fluid sparing: A 48-hour prospective study in conscious sheep. J Trauma 2000; 49: 251–63Elgjo, GI Traber, DL Hawkins, HK Kramer, GC
Cochran WG, Cox GM: Experimental Designs, 2nd edition. New York, John Wiley and Sons, 1992, pp 80–2
Van der Linden P, Gilbart E, Engelman E, Schmartz D, De Rood M, Vincent JL: Comparison of halothane, isoflurane, alfentanil, and ketamine in experimental septic shock. Anesth Analg 1990; 70: 608–17Van der Linden, P Gilbart, E Engelman, E Schmartz, D De Rood, M Vincent, JL
Diodato MD, Knoferl MW, Schwacha MG, Bland KI, Chaudry IH: Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. Cytokine 2001; 14: 162–9Diodato, MD Knoferl, MW Schwacha, MG Bland, KI Chaudry, IH
Knoferl MW, Angele MK, Diodato MD, Schwacha MG, Ayala A, Cioffi WG, Bland KI, Chaudry IH: Female sex hormones regulate macrophage function after trauma-hemorrhage and prevent increased death rate from subsequent sepsis. Ann Surg 2002; 235: 105–12Knoferl, MW Angele, MK Diodato, MD Schwacha, MG Ayala, A Cioffi, WG Bland, KI Chaudry, IH
Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: A placebo- controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139–43Bellomo, R Chapman, M Finfer, S Hickling, K Myburgh, J
Desjars P, Pinaud M, Potel G, Tasseau F, Touze M-D: A reappraisal of norepinephrine therapy in human septic shock. Crit Care Med 1987; 15: 134–7Desjars, P Pinaud, M Potel, G Tasseau, F Touze, M-D
Meadows D, Edwards JD, Wilkins RG, Nightingale P: Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988; 16: 663–6Meadows, D Edwards, JD Wilkins, RG Nightingale, P
Sautner T, Wessely C, Riegler M, Sedivy R, Gotzinger P, Losert U, Roth E, Jakesz R, Fugger R: Early effects of catecholamine therapy on mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin shock. Ann Surg 1998; 228: 239–48Sautner, T Wessely, C Riegler, M Sedivy, R Gotzinger, P Losert, U Roth, E Jakesz, R Fugger, R
Schmidt H, Secchi A, Wellmann R, Böhrer H, Bach A, Martin E: Effect of low-dose dopamine on intestinal villus microcirculation during normotensive endotoxaemia in rats. Br J Anaesth 1996; 76: 707–12Schmidt, H Secchi, A Wellmann, R Böhrer, H Bach, A Martin, E
Dhainaut JF, Edwards JD, Grootendorst AF, Nightingale P, Pinsky MR, Reinhart K, Shoemaker WC, Vincent JL: Practical aspects of oxygen transport: Conclusions and recommendations of the Round Table Conference. Intensive Care Med 1990; 16: S179–80Dhainaut, JF Edwards, JD Grootendorst, AF Nightingale, P Pinsky, MR Reinhart, K Shoemaker, WC Vincent, JL
Reinhart K, Hannemann L, Kuss B: Optimal levels of oxygen delivery in the critically ill. Intensive Care Med 1990; 16: S149–54Reinhart, K Hannemann, L Kuss, B
Shoemaker WC, Appel PL, Kram HB, Bishop M, Abraham E: Hemodynamic and oxygen transport monitoring to titrate therapy in septic shock. New Horiz 1993; 1: 145–59Shoemaker, WC Appel, PL Kram, HB Bishop, M Abraham, E
Shoemaker WC, Appel PL, Kram HB, Duarte D, Harrier HD, Ocampo HA: Comparison of hemodynamic and oxygen transport effects of dopamine and dobutamine in critically ill surgical patients. Chest 1989; 96: 120–6Shoemaker, WC Appel, PL Kram, HB Duarte, D Harrier, HD Ocampo, HA
Vincent JL, Roman A, Kahn RJ: Dobutamine administration in septic shock: Addition to a standard protocol. Crit Care Med 1990; 18: 689–93Vincent, JL Roman, A Kahn, RJ
Hannemann L, Reinhart K, Grenzer O, Meier-Hellmann A, Bredle DL: Comparison of dopamine to dobutamine and norepinephrine for oxygen delivery and uptake in septic shock. Crit Care Med 1995; 23: 1962–70Hannemann, L Reinhart, K Grenzer, O Meier-Hellmann, A Bredle, DL
Martin C, Viviand X, Arnaud S, Vialet R, Rougnon T: Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med 1999; 27: 1708–13Martin, C Viviand, X Arnaud, S Vialet, R Rougnon, T
Secchi A, Wellmann R, Martin E, Schmidt H: Dobutamine maintains intestinal villus blood flow during normotensive endotoxemia: An intravital microscopic study in the rat. J Crit Care 1997; 12: 137–41Secchi, A Wellmann, R Martin, E Schmidt, H
Nevière R, Chagnon JL, Vallet B, Lebleu N, Marechal X, Mathieu D, Wattel F, Dupuis BA: Dobutamine improves gastrointestinal mucosal blood flow in a porcine model of endotoxic shock. Crit Care Med 1997; 25: 1371–7Nevière, R Chagnon, JL Vallet, B Lebleu, N Marechal, X Mathieu, D Wattel, F Dupuis, BA
Duranteau J, Sitbon P, Teboul JL, Vicaut E, Anguel N, Richard C, Samii K: Effects of epinephrine, norepinephrine, or the combination of norepinephrine and dobutamine on gastric mucosa in septic shock. Crit Care Med 1999; 27: 893–900Duranteau, J Sitbon, P Teboul, JL Vicaut, E Anguel, N Richard, C Samii, K
James JH, Luchette FA, McCarter FD, Fischer JE: Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 1999; 354: 505–8James, JH Luchette, FA McCarter, FD Fischer, JE
Bakker J, Gris P, Coffernils M, Kahn RJ, Vincent JL: Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg 1996; 171: 221–6Bakker, J Gris, P Coffernils, M Kahn, RJ Vincent, JL
Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM, Bennett ED: A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med 1999; 27: 2361–6Rhodes, A Lamb, FJ Malagon, I Newman, PJ Grounds, RM Bennett, ED
Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–77Rivers, E Nguyen, B Havstad, S Ressler, J Muzzin, A Knoblich, B Peterson, E Tomlanovich, M
Webb AR, Moss RF, Tighe D, al Saady N, Bennett ED: The effects of dobutamine, dopexamine and fluid on hepatic histological responses to porcine faecal peritonitis. Intensive Care Med 1991; 17: 487–93Webb, AR Moss, RF Tighe, D al Saady, N Bennett, ED
Tighe D, Moss R, Heywood G, Al-Saady N, Webb A, Bennett D: Goal-directed therapy with dopexamine, dobutamine, and volume expansion: Effects of systemic oxygen transport on hepatic ultrastructure in porcine sepsis. Crit Care Med 1995; 23: 1997–2007Tighe, D Moss, R Heywood, G Al-Saady, N Webb, A Bennett, D
Fig. 1. Changes in mean arterial blood pressure (top  ) and cardiac output (bottom  ) in the four groups. Base represents the first measurement after 1 h of stabilization following laparotomy. Adrenergic agents were required after a mean of approximately 10 h. *P  < 0.05, control (CL) versus  dobutamine (DB)-norepinephrine (NE); #P  < 0.05, CL versus  norepinephrine; =P  < 0.05, dopamine (DP)-norepinephrine versus  dobutamine-norepinephrine.
Fig. 1. Changes in mean arterial blood pressure (top 
	) and cardiac output (bottom 
	) in the four groups. Base represents the first measurement after 1 h of stabilization following laparotomy. Adrenergic agents were required after a mean of approximately 10 h. *P 
	< 0.05, control (CL) versus 
	dobutamine (DB)-norepinephrine (NE); #P 
	< 0.05, CL versus 
	norepinephrine; =P 
	< 0.05, dopamine (DP)-norepinephrine versus 
	dobutamine-norepinephrine.
Fig. 1. Changes in mean arterial blood pressure (top  ) and cardiac output (bottom  ) in the four groups. Base represents the first measurement after 1 h of stabilization following laparotomy. Adrenergic agents were required after a mean of approximately 10 h. *P  < 0.05, control (CL) versus  dobutamine (DB)-norepinephrine (NE); #P  < 0.05, CL versus  norepinephrine; =P  < 0.05, dopamine (DP)-norepinephrine versus  dobutamine-norepinephrine.
×
Fig. 2. Changes in superior mesenteric artery (top  ) and femoral artery (bottom  ) blood flow in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
Fig. 2. Changes in superior mesenteric artery (top 
	) and femoral artery (bottom 
	) blood flow in the four groups. See figure 1for other details. =P 
	< 0.05, dopamine (DP)-norepinephrine (NE) versus 
	dobutamine (DB)-norepinephrine.
Fig. 2. Changes in superior mesenteric artery (top  ) and femoral artery (bottom  ) blood flow in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
×
Fig. 3. Changes of lactate concentration in arterial blood (top  ) and Pco2gap (bottom  ) in the four groups. See figure 1for other details. *P  < 0.05, CL versus  dobutamine (DB)-norepinephrine (NE); +P  < 0.05, norepinephrine versus  dobutamine- norepinephrine.
Fig. 3. Changes of lactate concentration in arterial blood (top 
	) and Pco2gap (bottom 
	) in the four groups. See figure 1for other details. *P 
	< 0.05, CL versus 
	dobutamine (DB)-norepinephrine (NE); +P 
	< 0.05, norepinephrine versus 
	dobutamine- norepinephrine.
Fig. 3. Changes of lactate concentration in arterial blood (top  ) and Pco2gap (bottom  ) in the four groups. See figure 1for other details. *P  < 0.05, CL versus  dobutamine (DB)-norepinephrine (NE); +P  < 0.05, norepinephrine versus  dobutamine- norepinephrine.
×
Fig. 4. Cumulative urine output in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
Fig. 4. Cumulative urine output in the four groups. See figure 1for other details. =P 
	< 0.05, dopamine (DP)-norepinephrine (NE) versus 
	dobutamine (DB)-norepinephrine.
Fig. 4. Cumulative urine output in the four groups. See figure 1for other details. =P  < 0.05, dopamine (DP)-norepinephrine (NE) versus  dobutamine (DB)-norepinephrine.
×
Fig. 5. Kaplan-Meier survival curves for the four groups: control (▪), norepinephrine (▾), dopamine-norepinephrine (▴), and dobutamine-norepinephrine (⧫). P  < 0.05, control (CL) versus  dopamine-norepinephrine, norepinephrine, or dobutamine-norepinephrine, or norepinephrine versus  dopamine-dobuta-mine-norepinephrine.
Fig. 5. Kaplan-Meier survival curves for the four groups: control (▪), norepinephrine (▾), dopamine-norepinephrine (▴), and dobutamine-norepinephrine (⧫). P 
	< 0.05, control (CL) versus 
	dopamine-norepinephrine, norepinephrine, or dobutamine-norepinephrine, or norepinephrine versus 
	dopamine-dobuta-mine-norepinephrine.
Fig. 5. Kaplan-Meier survival curves for the four groups: control (▪), norepinephrine (▾), dopamine-norepinephrine (▴), and dobutamine-norepinephrine (⧫). P  < 0.05, control (CL) versus  dopamine-norepinephrine, norepinephrine, or dobutamine-norepinephrine, or norepinephrine versus  dopamine-dobuta-mine-norepinephrine.
×
Fig. 6. Histologic alterations in the small intestine and lung. Open bars represent the number of animals in which an alteration was observed, and solid bars represent the sum of the severity scores for each type of alteration in the entire group. CL = control group; NE = norepinephrine; DP+NE = dopamine-norepinephrine; DB+ NE = dobutamine-norepinephrine; C = congestion; I = interstitial inflammation; E = edema; H = hemorrhagic alveolitis. *P  < 0.05 versus  CL.
Fig. 6. Histologic alterations in the small intestine and lung. Open bars represent the number of animals in which an alteration was observed, and solid bars represent the sum of the severity scores for each type of alteration in the entire group. CL = control group; NE = norepinephrine; DP+NE = dopamine-norepinephrine; DB+ NE = dobutamine-norepinephrine; C = congestion; I = interstitial inflammation; E = edema; H = hemorrhagic alveolitis. *P 
	< 0.05 versus 
	CL.
Fig. 6. Histologic alterations in the small intestine and lung. Open bars represent the number of animals in which an alteration was observed, and solid bars represent the sum of the severity scores for each type of alteration in the entire group. CL = control group; NE = norepinephrine; DP+NE = dopamine-norepinephrine; DB+ NE = dobutamine-norepinephrine; C = congestion; I = interstitial inflammation; E = edema; H = hemorrhagic alveolitis. *P  < 0.05 versus  CL.
×
Fig. 7. Representative light micrographs of pulmonary, hepatic, and renal biopsies in one sheep from the control group (sheep No. 5801, hematoxylin and eosin, ×100). Kidney (top left  ); lung (bottom left  ); liver (bottom right  ).
Fig. 7. Representative light micrographs of pulmonary, hepatic, and renal biopsies in one sheep from the control group (sheep No. 5801, hematoxylin and eosin, ×100). Kidney (top left 
	); lung (bottom left 
	); liver (bottom right 
	).
Fig. 7. Representative light micrographs of pulmonary, hepatic, and renal biopsies in one sheep from the control group (sheep No. 5801, hematoxylin and eosin, ×100). Kidney (top left  ); lung (bottom left  ); liver (bottom right  ).
×
Table 1. Hemodynamic and Metabolic Parameters
Image not available
Table 1. Hemodynamic and Metabolic Parameters
×